{"url_path":"/sec/sgp/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1778922/0001778922-26-000033-index.html","accession_number":"0001778922-26-000033","cik":"0001778922","ticker":"SGP","issuer_name":"SpyGlass Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1778922/0001778922-26-000033-index.html","primary_entity_key":"0001778922","primary_entity_name":"SpyGlass Pharma, Inc."},"word_count":84,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d)Exhibits.\n\nExhibit Number\n\nDescription\n\n99.1\n\n[Press Release of SpyGlass Pharma, Inc., dated May 14, 2026](exhibit991-8kprx051426.htm)\n\n104\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n1\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nSPYGLASS PHARMA, INC.\n\nBy:\n\n/s/ Jean-Frédéric Viret, Ph.D.\n\nJean-Frédéric Viret, Ph.D.\n\nDate: May 14, 2026\n\nChief Financial Officer\n\n2"}